正常卵巢及卵巢肿瘤雌、孕激素受体的研究  

Study on the clinical biology of estrogen and progesterone receptors in normal and neoplastic human ovary

作　　者：王建六[1] 任品金[1] 许心杰[1] 

机构地区：[1]河南医科大学第三附属医院妇产科

出　　处：《河南医科大学学报》1993年第2期134-136,共3页Journal of Henan Medical University

摘　　要：采用酶联亲和组化法对15例正常卵巢组织、20例良性、48例恶性卵巢肿瘤的雌激素受体(ER)、孕激素受体(PgR)进行测定。结果显示:①ER、PgR阳性率在正常卵巢组织为26.67%和60%,良性肿瘤为55.00%和50.00%,恶性肿瘤为56.25%和54.17%。②恶性肿瘤患者不同年龄、行经年数、临床分期及术前有无化疗的ER、PgR状态无显著性差异(P>0.05),而不同病理分级、月经状态下的ER、PgR状态有显著差异(P<0.05)。提示:正常卵巢及卵巢病变组织中ER、PgR阳性率不同。The estrogen receptor(ER)and the progesterone receptor(PgR) were tested with enzyme-linkingaffinity histochemistry method on the fresh ovarian tissues from 15 normal individuals, and 20 benignand 48 malignant tumors. At the same time, the clinical features of the patients were analysed tounderstand the relation between them. The results are as follows: ①the positive rates of ER and PgRin normal ovarian tissues were 26. 26% and 60%,in benign tumors 55% and 50%,and in malignanttumors 56. 25% and 54. 14%;②there was no relation between ER and PgR and the patient's age,the number of menstruation year, the clinical stage, and undergoing chemotherapy or not beforeoperation; ③the positive rate of ER was lower in premenopause than in postmenoopause(P<0. 05),The state of ER and PgR was associated with the pathological grade (P<0. 05). This study suggeststhat the presence of ER and PgR in malignant ovarian tumors might help to select the patients suitablefor hormonal therapy,and that ER and PgR may be potential markers of tumor differentiation.

关 键 词：卵巢肿瘤 雌激素 孕激素 受体 

分 类 号：R737.310.3[医药卫生—肿瘤]